Pomak I finally got my order completely filled. Have picked

New Post Public Reply Private Reply Replies (2) Message Board
highflier pomak #394
Pomak I finally got my order completely filled. Have picked up 10 million in the past 6 days. Now is the time to be adding if you are looking to increase your position. Only buy on the bid at .0019. In the past 2 days my 1 order has been over 70% of the volume. Goes to show trading is very little. Now is the time to buy! Orders below:

Order Details for Order # 19 Close
Order Type Quantity Security Price Type Term Price Other Order Details
Buy
5,000,000
SOLOS ENDOSCOPY INC COM PAR $0.0001 (SNDY)
Limit GT 60 0.0019  
Transaction Status Order Description Date & Time Quantity Price
Executed
Commission
/Fee
Order Placed Buy 5,000,000 SNDY Limit GT 60 09/24/13 09:47:00 AM EDT 5,000,000.00 -- 9.99
Executed Buy 56,555 SNDY Limit GT 60 09/25/13 11:10:18 AM EDT 56,555.00 0.0019 9.99
Executed Buy 3,000,000 SNDY Limit GT 60 09/25/13 03:21:20 PM EDT 3,000,000.00 0.0019 0.00
Executed Buy 1,943,445 SNDY Limit GT 60 09/26/13 10:30:47 AM EDT 1,943,445.00 0.0019 9.99

Order Details for Order # 18 Close
Order Type Quantity Security Price Type Term Price Other Order Details
Buy
5,000,000
SOLOS ENDOSCOPY INC COM PAR $0.0001 (SNDY)
Limit GT 60 0.0019  
Transaction Status Order Description Date & Time Quantity Price
Executed
Commission
/Fee
Order Placed Buy 5,000,000 SNDY Limit GT 60 09/20/13 03:27:30 PM EDT 5,000,000.00 -- 9.99
Executed Buy 5,000,000 SNDY Limit GT 60 09/23/13 11:34:13 AM EDT 5,000,000.00 0.0019 9.99

Take care my friend,
Mike

CYduct Diagnostics Inc. (CYDX) Stock Research Links

CYDX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

USDA Under Scrutiny as ASPCA Reports on Puppy Mill Violations

Updated Category News Views 322

ASPCA's Shocking Report on Puppy Mill Violations In a recent analysis by the ASPCA, alarming statistics have surfaced regarding animal welfare violations at USDA-licensed commercial dog breeding facilities. The findings reveal that in a given year, substantial breaches of care standards were documented, yet no actions were taken to ensure the safety of the animals....

Continue Reading
PowerReviews Unveils Partner Program to Amplify UGC Value

Updated Category News Views 1653

PowerReviews Launches Comprehensive Partner Program PowerReviews, a reputable name backed by 1WorldSync, has initiated an exciting Partner Program aimed at revolutionizing the way user-generated content (UGC) is leveraged. This initiative is designed to not only boost productivity but also facilitate enhanced revenue opportunities for partners who promote its advanced...

Continue Reading
Turnspire Capital Partners Expands Portfolio with GHP Group

Updated Category News Views 81

Turnspire Capital Partners pulled the trigger on acquiring GHP Group back in 2024, a move that sent shockwaves through the consumer product landscape. This was no random buy; GHP's got its fingers in the pie of outdoor living products—think patio heaters and grills—all under reputable brands like Dyna-Glo and Pleasant Hearth. GHP Group: A Heavyweight Player in Outdoor...

Continue Reading
MPI Corporation Launches Groundbreaking 250 GHz Probe System

Updated Category News Views 187

Enhancing Precision in Semiconductor Testing In the fast-evolving world of semiconductor technology, precision and performance are critical. MPI Corporation has once again demonstrated its innovative spirit by unveiling a revolutionary 250 GHz broadband test solution. This state-of-the-art system combines the power of the TITAN™ Probes and MPI's extensive expertise in...

Continue Reading
Passage Bio's Gene Therapy Strategy: Hope for Dementia Treatments

Updated Category News Views 76

Promising Advances in Gene Therapy Recently, Passage Bio, Inc. (NASDAQ: PASG), a pioneering company in genetic medicine, showcased groundbreaking preclinical and interim clinical results for its gene therapy product, PBFT02. This was presented at a major congress focused on gene and cell therapy. Designed specifically to target frontotemporal dementia associated with GRN...

Continue Reading